Allan Gibofsky, MD, JD, FACP, FCLM (Chair/Moderator)
Professor of Medicine and Public Health
Weill Medical College of Cornell University
Attending Rheumatologist, Hospital for Special Surgery
New York, NY
Steven Berney, MD
Professor Emeritus, Medicine
Temple University School of Medicine
Section of Rheumatology
Lauren Collins, MD
Department of Family and Community Medicine
Jefferson Medical College
Thomas Jefferson University
Estimated amount of time to complete: 1 hour
Rheumatoid arthritis (RA) is a chronic inflammatory disease that causes joint pain, stiffness, and swelling, and increases the risk of systemic conditions such as cardiovascular disease. RA currently affects 1.3 million people in the United States, and the incidence of RA is on the rise in women. Without early treatment that emphasizes tight control of disease activity, RA progresses to cause joint destruction, decreased physical functioning, and reduced quality of life. Therefore, early treatment initiation and ongoing monitoring of therapeutic response are critical to improving patient outcomes.
Rheumatologists and other clinicians involved in the management of RA have the opportunity to improve outcomes in patients with RA by expanding their skills to 1) initiate treatment as early as possible with a disease-modifying antirheumatic drug (DMARD) and 2) ensure individualized treatment targets are reached. The goal of this continuing education activity is to expand the ability of rheumatologists and other clinicians involved in the management of RA to implement best practices based on the latest clinical evidence, thereby protecting functional status, enhancing quality of life, and reducing disease burden for patients with RA.
In this video roundtable, faculty will discuss the importance of early diagnosis and factors to consider when selecting and initiating therapy. In addition, faculty will discuss strategies to improve collaboration between primary care clinicians and specialists to ensure optimal care for patients with RA.
Rheumatologists, primary care physicians, nurse practitioners, physician assistants and other health care clinicians interested and involved in the treatment of patients with RA.
Upon completion of this educational activity, the participant should be able to:
Identify which patients with newly diagnosed RA require early and aggressive treatment due to an increased risk of erosive disease.
Initiate first-line DMARD therapy in patients with early RA in accordance with current guidelines and clinical evidence.
It is the policy of Temple University School of Medicine; The Albert J. Finestone, MD Office for Continuing Medical Education to insure balance, independence, objectivity, and scientific rigor in all of its sponsored or jointly sponsored educational programs. All faculty, program planning committee members, and Temple University School of Medicine Continuing Medical Education staff participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentation(s).
PLANNING COMMITTEE DISCLOSURE STATEMENT
Planning committee members have no financial relationships to disclose.
FACULTY DISCLOSURE STATEMENT
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.
Dr. Gibofsky discloses the following relationships:
Consultant: Abbott, Amgen, Genentech/Roche, Pfizer, UCB, Iroko, Horizon, Takeda.
Speakers’ Bureau: Abbott, Amgen, Genentech/Roche, Pfizer, UCB.
Stockholder: Abbott, Amgen, Johnson and Johnson, GlaxoSmithKline, Pfizer, Bristol-Myers Squibb.
Dr. Berney has no relevant financial relationships to disclose.
Dr. Collins has no relevant financial relationships to disclose.
Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.
Certification Statement: Temple University School of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
There is no fee to participate and receive credit.
Credit Provider Contact Information
School of Medicine
The Albert J. Finestone, MD Office for CME
3500 North Broad Street Philadelphia, PA 19140
Commercial Support Statements
This activity is supported through an independent educational grant from Abbott Laboratories.
This activity is supported through an independent educational grant from Amgen Inc.
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7
• Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. You may start as a GUEST, but to claim credit, you must be a member. If you are not already registered as a user of this website, visit the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 60 minutes to complete.
After the program has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen. A credit statement/certificate will be awarded for a score of 70% or better and may be printed immediately after passing the post-test.
Copyright © 2012. Temple University School of Medicine. All rights reserved.
Presented by Temple University School of Medicine and MCM Education.
The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, Abbott Laboratories or Amgen Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.
To view our privacy policies, please visit: http://www.cmecorner.com/privacy.asp